© Borgis - Medycyna Rodzinna 4, p. 91-95
*Aleksandra Krause, Paulina Górska, Janusz Ślusarczyk
Adiuwanty – substancje podnoszące skuteczność szczepionek – część II
ADJUVANTS – SUBSTANCES STIMULATING IMMUNE RESPONSE – PART II
Zakład Badania Surowic i Szczepionek Państwowego Zakadu Higieny
Kierownik Zakładu: prof. dr hab. med. Janusz Ślusarczyk
Summary
Adjuvants that are constituents of many different preparations used for active immunization, significantly influence the process of immunological reaction against the antigen, enhancing or modulating its profile. Optimal adjuvant system should provide high effectiveness of vaccines and allergen preparations and guarantee maximal safety. New generation vaccines produced with advanced genetic engineering techniques, containing synthetic antigens or antigen fragments are much safer than conventional preparations, but also much less immunogenic. New adjuvant formulas are therefore elaborated to obtain sufficient immunostimulation. Aluminium hydroxide or aluminium phosphate are the most universal adjuvant nowadays. New experiments are conducted however worldwide to elaborate better adjuvants than aluminum compounds. In the second part of the paper entitled "Adjuvants – substances stimulating immunological response” physico-chemical properties and mechanisms of action of new generation adjuvants were focused. Main groups of these substances were characterized, such as adjuvants derived from bacteria, liposomes, archaeosomes, adjuvant-active nonionic block copolymers, microspheres or cytokines, many different adjuvant formulas were also specified, among others MPL, CpG, enterotoxins and MDP.
Key words: adjuvants, vaccines, immune response, immunostimulator, antigen presenting cell (APC)
Piśmiennictwo
1. Mesa C., Fernandez L.E.: Challenges facing adjuvants for cancer immunotherapy. Immunol Cell. Biol. 2004; 82, 6: 644-50.2. Chodaczek G.: Adiuwanty jako czynniki podnoszące skuteczność szczepionek. Postępy Hig. Med. Dosw., 2004; 58: 47-59. 3. Gupta R.K., et al.: Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11, 3: 293-306.4. Dzierzbicka K., Kołodziejczyk A.M.: Adiuwanty - niezbędne składniki szczepionek nowej generacji. Postępy Biochemii 2006; 52, 2: 204-211.5. Persing D.H., et al.: Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002; 10 (10 Suppl): S32-37.6. Fiejka M., Aleksandrowicz J.: Perspektywy zastosowania w szczepionkach nowych adiuwantów. Ślusarczyk J. Szczepienia i Szczepionki Teraźniejszość i Przyszłość. Referaty wygłoszone podczas Konferencji Naukowej Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych. Bydgoszcz, 16-18.09.1998. SmithKline Beecham Polska Sp. z o.o. 1999, 167-179.7. Ismaili J., et al.: Monophosphoryl lipid A activates both human dendritic cells and T. cells. J. Immunol., 2002; 168: 926-932.8. Jiang Z.H., Koganty R.R.: Synthetic vaccines: The role of adjuvants in immune targeting. Curr. Med. Chem., 2003; 10: 1423-1439.9. Thoelen S., et al.: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16, 7: 708-14.10. Thoelen S., et al.: A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001; 19, 17-19: 2400-3.11. Ambrosch F., et al.: A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000; 18, 20: 2095-101.12. McCluskie M.J., Weeratna R.D.: Novel adjuvant systems. Curr. Drug. Targets Infect Disord., 2001; 1, 3: 263-71.13. Erb K.J., Wohlleben G.: Novel vaccines protecting against the development of allergic disorders: a double-edged sword? Curr. Opin. Immunol., 2002; 14: 633-643.14. Krieg A.M.: The role of CpG motifs in innate immunity. Curr. Opin. Immunol., 2000; 12: 35-43.15. Williams N.A., et al.: Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today 1999; 20: 95-101.16. Gagliardi M.C., et al.: Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol., 2000; 30: 2394-2403.17. Glenn G.M., et al.: Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun., 1999; 67: 1100-1106.18. Todate A., et al.: Muramyl dipeptide-Lys stimulates the function of human dendritic cells. J. Leukoc. Biol., 2001; 70: 723-729.19. Fast D.J., Vosika G.J.: The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens. Vaccine 1997; 15: 1748-1752.20. Bahr G.M.: Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunomodulator murabutide. J. Antimicrob. Chemother 2003; 51: 5-8.21. Ando S., et al.: Effect of cholesterol or phospholipids incorporation on vesicle formation of muramyldipeptide derivative B30-MDP. Prog. Colloid. Polym. Sci. 1996; 274: 178-185.22. Maurer N., et al.: Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther., 2001; 1, 6: 923-47.23. Green S., et al.: Liposomal vaccines. Adv. Exp. Med. Biol., 1995; 383: 83-92.24. Gluck R.: Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 1999; 17: 1782-1787.25. Patel G.B., Chen W.: Archaeosome immunostimulatory vaccine delivery system. Curr. Drug. Deliv., 2005; 2, 4: 407-21.26. Patel G.B., Sprott G.D.: Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery system. Crit. Rev. Biotechnol., 1999; 19: 317-357.27. Krishnan L., Dennis Sprott G.: Archaeosomes as self-adjuvanting delivery system for cancer vaccines. J. Drug. Target., 2003; 11, 8-10: 515-24.28. Patel G.B., et al.: Archaeosomes as adjuvants for combination vaccines. J. Liposome Res., 2004; 14, 3-4: 191-202.29. Newman M.J.: Vaccines adjuvant. Expert Opinion on Therapeutic Patents 2000; 10: 279-314.30. Hughes H.P.: Cytokine adjuvants: lessons from the past - guidelines for the future? Vet Immunol Immunopathol 1998; 63: 131-138.31. Van Slooten M.L., et al.: Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. Biochim. Biophys. Acta 2001; 1531: 99-110.32. Ben-Yehuda A., et al.: Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 2003; 21: 3169-3462.33. Freidag B.I., et al.: CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun. 2000; 68: 2948-2953.34. Kenney R.T., et al.: Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol., 1999; 163: 4481-4488.35. Arulanandam B.P., et al.: IL-12 is a potent neonatal vaccine adjuvant. Eur. J. Immunol., 1999; 29: 256-264.36. Ahlers J.D., et al.: Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol., 2001; 13: 897-908.37. Pascual D.M., et al.: Adjuvants: Present regulatory challenges. Vaccine 2006; 24S2: S2/88-S2/89.
otrzymano/received: 2007-10-03
zaakceptowano/accepted: 2007-10-16
Adres/address:
*Aleksandra Krause
Pracownia Immunochemii Zakład Badania Surowic i Szczepionek
Instytut Naukowo-Badawczy
ul. Chocimska 24, 00-791 Warszawa
tel.: (0-22) 542-13-47
e-mail: akrause@pzh.gov.pl
